238 related articles for article (PubMed ID: 26169562)
1. Comparative evaluation of HMG CoA reductase inhibitors in experimentally-induced myocardial necrosis: Biochemical, morphological and histological studies.
Variya BC; Patel SS; Trivedi JI; Gandhi HP; Rathod SP
Eur J Pharmacol; 2015 Oct; 764():283-291. PubMed ID: 26169562
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective effect of vincristine on isoproterenol-induced myocardial necrosis in rats.
Panda S; Kar A; Ramamurthy V
Eur J Pharmacol; 2014 Jan; 723():451-8. PubMed ID: 24201307
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
4. [Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
Ichihara K; Satoh K; Yamamoto A; Hoshi K
Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():142P-149P. PubMed ID: 10629871
[TBL] [Abstract][Full Text] [Related]
5. Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats.
Kalonia H; Kumar P; Kumar A
Behav Brain Res; 2011 Jan; 216(1):220-8. PubMed ID: 20696189
[TBL] [Abstract][Full Text] [Related]
6. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
[TBL] [Abstract][Full Text] [Related]
7. Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat.
Zhou R; Xu Q; Zheng P; Yan L; Zheng J; Dai G
Eur J Pharmacol; 2008 May; 586(1-3):244-50. PubMed ID: 18384769
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective effect of rosuvastatin against isoproterenol-induced myocardial infarction injury in rats.
Yu Y; Jin L; Zhuang Y; Hu Y; Cang J; Guo K
Int J Mol Med; 2018 Jun; 41(6):3509-3516. PubMed ID: 29568858
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
10. Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
Minard LV; Corkum A; Sketris I; Fisher J; Zhang Y; Saleh A
PLoS One; 2016; 11(7):e0158608. PubMed ID: 27434392
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin treatment on isoproterenol-induced myocardial infarction in rats.
Trivedi CJ; Balaraman R; Majithiya JB; Bothara SB
Pharmacology; 2006; 77(1):25-32. PubMed ID: 16567950
[TBL] [Abstract][Full Text] [Related]
13. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Andrews TC; Ballantyne CM; Hsia JA; Kramer JH
Am J Med; 2001 Aug; 111(3):185-91. PubMed ID: 11530028
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic clues in the cardioprotective effect of Terminalia arjuna bark extract in isoproterenol-induced chronic heart failure in rats.
Parveen A; Babbar R; Agarwal S; Kotwani A; Fahim M
Cardiovasc Toxicol; 2011 Mar; 11(1):48-57. PubMed ID: 21116736
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma.
Zhou YY; Zhu GQ; Wang Y; Zheng JN; Ruan LY; Cheng Z; Hu B; Fu SW; Zheng MH
Oncotarget; 2016 Apr; 7(16):21753-62. PubMed ID: 26943041
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Rosenson RS; Tangney CC; Schaefer EJ
Atherosclerosis; 2001 Apr; 155(2):463-6. PubMed ID: 11254918
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Zhou Z; Rahme E; Abrahamowicz M; Tu JV; Eisenberg MJ; Humphries K; Austin PC; Pilote L
CMAJ; 2005 Apr; 172(9):1187-94. PubMed ID: 15851712
[TBL] [Abstract][Full Text] [Related]
18. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
19. Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs.
Satoh K; Ichihara K
J Cardiovasc Pharmacol; 2000 Feb; 35(2):256-62. PubMed ID: 10672858
[TBL] [Abstract][Full Text] [Related]
20. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
